Categories Earnings, Health Care

Sunesis Pharmaceutical (SNSS): Q4 2019 Earnings Snapshot

pharma stocks
Image for representation (Photo by Drew Hays on Unsplash)

— Sunesis Pharmaceuticals (NASDAQ: SNSS) reported loss of $0.05 per share in the fourth quarter of 2019, vs $0.07 per share loss expected. 

— Net revenue rose to $2.1 billion, vs. $310,000 expected. The growth in topline was driven by revenue recognized from the upfront payments received under the license agreements with DOT-1 and Denovo.  

— Cash and cash equivalents rose to $34.6 million, from $13.7 million a year ago. The growth was primarily due to net proceeds from the issuance of common and preferred stock, and proceeds from the SVB loan. 

— SNSS shares fell over 2% immediately following the announcement.   

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Also Read:  Oak Street Health, Inc. (OSH) Q2 2020 Earnings Call Transcript

Most Popular

Palantir Technologies (PLTR) to start trading tomorrow through direct listing

The IPO market witnessed a boom in 2020, despite the pandemic weakening the macro environment. Many tech companies have witnessed a blockbuster listing this year and few more tech firms

Micron (MU) Q4 earnings, revenue top expectations

Micron Technology Inc. (NASDAQ: MU) reported strong earnings and revenue growth for the fourth quarter of 2020, benefitting from the pandemic-driven digital transformation spree. However, the company's stock dropped during

After a strong year thus far, Zynga (ZNGA) appears well-positioned for 2021 as well

Mobile game company Zynga Inc. (NASDAQ: ZNGA) has seen its stock gain 49% since the beginning of this year. The company registered strong results in the first half of 2020

Top